Jake Alden Kushner MD FAAP
"McNair Medical Institute Scholar\r\nChief of Pediatric Diabetes and
Join to View Full Profile
3615 Civic Center BlvdCHOP Endocrine Arc 802CPhiladelphia, PA 19104
Phone+1 267-426-5717
Fax+1 215-590-1605
Are you Dr. Kushner?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Jake Kushner, MD is a pediatric endocrinologist in Philadelphia, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania, Texas, and Massachusetts.
Education & Training
Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Endocrinology, 1997 - 2000
Brown UniversityResidency, Pediatrics, 1994 - 1997
Albany Medical CollegeClass of 1994
Certifications & Licensure
TX State Medical License 2011 - 2025
PA State Medical License 2003 - 2012
MA State Medical License 2000 - 2005
RI State Medical License 1995 - 2004
American Board of Pediatrics Pediatric Endocrinology
Publications & Presentations
PubMed
- 2 citationsUnsupervised Anomaly Detection to Characterize Heterogeneity in Type 2 Diabetes.Peniel N Argaw, Jake A Kushner, Isaac S Kohane
AMIA Joint Summits on Translational Science Proceedings. AMIA Joint Summits on Translational Science. 2023-01-01 - 13 citationsEffects of Sotagliflozin Combined with Intensive Insulin Therapy in Young Adults with Poorly Controlled Type 1 Diabetes: The JDRF Sotagliflozin StudyBruce W. Bode, Eda Cengiz, R. Paul Wadwa, Phillip Banks, Thomas Danne
Diabetes Technology & Therapeutics. 2021-01-01 - 19 citationsDiabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies.Anne L. Peters, Darren K. McGuire, Thomas Danne, Jake A. Kushner, Helena W. Rodbard
Diabetes Care. 2020-09-07
Press Mentions
From Celiac to COVID, Texas Tech Company Pioneering at-Home Health TestsApril 21st, 2021
GlySens Incorporated Closes Incremental $15 Million Financing Supporting on-Going Clinical Evaluations and First-in-Man Study of the Third Generation Eclipse® 3 ICGM® SystemJune 12th, 2020
State of the Art Review in Gonadal Dysgenesis: Challenges in Diagnosis and ManagementApril 14th, 2020- Join now to see all
